Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency

Annu Rev Med. 1997;48:93-102. doi: 10.1146/annurev.med.48.1.93.

Abstract

Intravenous immunoglobulin (IVIG) concentrates were originally developed as replacement therapy for individuals with primary deficiencies of the immune system. However, in various well-designed, controlled clinical trials, the ability of IVIG to prevent and possibly treat infections in patients with secondary immune deficiencies has also been considered. In this review, we briefly consider these different applications and suggest whether the data are sufficient to employ IVIG in these clinical settings.

Publication types

  • Review

MeSH terms

  • Acquired Immunodeficiency Syndrome / immunology
  • Acquired Immunodeficiency Syndrome / therapy
  • Clinical Trials as Topic
  • Humans
  • Immunization, Passive / methods*
  • Immunologic Deficiency Syndromes / immunology
  • Immunologic Deficiency Syndromes / therapy*
  • Infusions, Intravenous
  • Opportunistic Infections / immunology
  • Opportunistic Infections / therapy*
  • Treatment Outcome